Following Recent FDA Clearance for Cholecystectomy, the Company is now 510(k) pending for Gynecology. This Submission Builds On Extensive Global Clinical Experience in Gynecology and Continues CMR’s U.S. Market Expansion.
CMR Surgical, the global surgical robotics business, today announce that it has received CE and UKCA Marks for its Versius Surgical System (Versius) in paediatric surgery, marking the Company’s first regulatory clearance for treating children. The approval has been received for abdominal surgery in children and infants under the age of 18.
CMR Surgical, the global surgical robotics business, today announce that it has received CE and UKCA Marks for its Versius Surgical System (Versius) in paediatric surgery, marking the Company’s first regulatory clearance for treating children. The approval has been received for abdominal surgery in children and infants under the age of 18.
CMR Surgical, the global medical technology company, today announces its second-generation surgical robotic platform, Versius Plus, has received 510(k) clearance from the United States Food and Drug Administration (FDA) for cholecystectomy procedures.
Versius—the second most utilised soft tissue surgical robot in the world—has now been used in over 30,000 surgical cases globally
CMR Surgical has closed a financing round of more than $200 million, backed by existing investors and new investor Trinity Capital
CMR Surgical has closed a financing round of more than $200 million, backed by existing investors and new investor Trinity Capital
CMR Surgical has closed a financing round of more than $200 million, backed by existing investors and new investor Trinity Capital
CMR Surgical has closed a financing round of more than $200 million, backed by existing investors and new investor Trinity Capital
Versius—the second most utilised soft tissue surgical robot in the world—has now been used in over 30,000 surgical cases globally